Pyxis Oncology is a technology company.
Pyxis Oncology has raised $172.0M across 2 funding rounds.
Key people at Pyxis Oncology.
Pyxis Oncology has raised $172.0M in total across 2 funding rounds.
Key people at Pyxis Oncology.
Pyxis Oncology is a clinical-stage biopharmaceutical company developing next-generation therapeutics, including antibody-drug conjugates (ADCs) and monoclonal antibody (mAb) immunotherapies, to target difficult-to-treat cancers and improve patient outcomes.[1][4] It serves cancer patients by advancing a differentiated portfolio of clinical assets that specifically target tumor cells and overcome immune suppression in the tumor microenvironment (TME), addressing unmet needs in cancers unresponsive to existing therapies.[1][2][4] The company has demonstrated growth momentum through recent positive preliminary Phase 1 data for its lead ADC candidate, micvotabart pelidotin (MICVO), in recurrent/metastatic head and neck squamous cell carcinoma as of December 2025, alongside active pipeline development and participation in investor conferences.[4]
Pyxis Oncology was founded in 2019 by Longwood Fund, with initial financing led by Bayer, building on the groundbreaking research of Dr. Thomas Gajewski, a leading expert in T cell immunology who has studied the tumor microenvironment for over two decades.[2] Dr. Gajewski's work unlocked new insights into turning immunologically "cold" tumors "hot" by restoring T cell activity, leading Pyxis to identify novel immunoregulatory targets distinct from traditional models derived from infectious disease research.[2] Early traction came from preclinical proof-of-concept studies validating these targets for potential monotherapies or combinations, establishing a pipeline of antibodies focused on tumor-reactive T cells.[2] The company has since assembled a world-class management team with deep oncology R&D experience, successfully building public biotech firms and advancing innovative medicines.[1]
Pyxis rides the surging wave of precision oncology, particularly ADCs and next-gen immunotherapies, amid market forces favoring targeted therapies for resistant cancers where traditional treatments fail.[1][3][4] Timing is ideal as ADC technology matures—enabling direct tumor targeting—and IO evolves beyond PD-1 inhibitors to address immune-cold tumors, a large unmet need highlighted by Pyxis's TME expertise.[2][4] This positions Pyxis to influence the ecosystem by expanding treatable patient populations, fostering combinations with existing therapies, and contributing preclinical/clinical data that could redefine standards for hard-to-treat solid tumors like head and neck cancers.[4]
Pyxis Oncology is poised for pipeline milestones, with MICVO Phase 1 data signaling potential registration paths and broader ADC/IO combinations on the horizon.[4] Trends like ADC payload innovations and TME-targeted combos will shape its trajectory, potentially amplifying influence through partnerships or approvals that serve underserved patients. As it liberates science to cure cancer, Pyxis stands out in oncology's high-stakes race, transforming difficult-to-treat cases into addressable opportunities.[1]
Pyxis Oncology has raised $172.0M in total across 2 funding rounds.
Pyxis Oncology's investors include Pfizer Venture Investments, Agent Capital, Longwood Fund.
Pyxis Oncology has raised $172.0M across 2 funding rounds. Most recently, it raised $150.0M Series B in March 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Mar 1, 2021 | $150.0M Series B | Pfizer Venture Investments | |
| Jul 1, 2019 | $22.0M Series A | Agent Capital, Longwood Fund |
